- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approved the expansion of reimbursement coverage for its FreeStyle Libre 2 ...

Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. This system comes with optional glucose alarms ...

- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms 1 to alert users when their glucose is high or low without scanning - Now for ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently, i "Sensor-based glucose ...

A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin 1 Expanded reimbursement facilitates wider access to continuous ...